Posaconazole oral suspension (PCZ-susp) can display a variable degree of inter and intra-individual absorption. However, there is no agreement on the need of plasmaposaconazole-concentration (PPC) monitoring as a routine practice in patients receiving
Introduction
Posaconazole (PCZ) is a broad-spectrum triazole antifungal agent with licensed indication for primary antifungal prophylaxis (PAP) in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients undergoing intensive chemotherapy and in patients who develop a Graft versus Host Disease (GvHD) after allogeneic stem cell transplant (allo-SCT). [1] [2] [3] [4] PCZ oral suspension (PCZ-susp) is widely used since several years and a new PCZ delayed-release tablet (PCZtab) formulation is now commercially available. The main difference of the two formulations is represented by the bioavailability. While PCZ-susp can display a large variable degree of inter-and intra-individual absorption affected by food (increased oral bioavailability with food, particularly fatty food or nutritional supplements, reduced absorption with fasting), gastric pH (increased absorption with an acidic environment and reduced absorption if concomitant use of proton pump inhibitors [PPIs]) and gastrointestinal inflammation, PCZ-tab is characterized by better systemic availability enabling once-daily administration, and absorption that is unaffected by the above factors. [5] [6] [7] [8] These pharmacokinetic differences may be clinically relevant considering that lower plasma PCZ concentrations (PPC) related to an inadequate absorption have a potential impact on the systemic drug exposure with subsequent increased risk of treatment failure. [9] [10] [11] [12] In view of the above, the measurement of the PPC has been recommended during PCZ-susp treatment, while it seems to be less important in patients taking PCZ-tab. 8, [11] [12] [13] . The pharmacokinetic differences between the two formulations and the difficulties in the PPC monitoring as a routine practice leave envisage a replacement of the PCZ-susp by the PCZ-tab in the clinical practice. Nevertheless, it should be considered that in patients with dysphagia or requiring feeding tubes PCZ-susp may be preferred, therefore the availability of this formulation still seems necessary in the clinical practice.
There are limited data on the impact of PPC monitoring as a routine practice in patients taking PCZ-susp outside of the setting of clinical licensing trials. In particular, it is not clear if and when measurement of PPC should be considered a standard of care or can be avoided when using PCZ-susp in prophylaxis.
In this prospective, multicenter study we evaluated the interpatient variability of PPCs in a "real life" scenario of acute leukemia (AL) patients submitted to intensive chemotherapy and allo-SCT recipients receiving PCZ-susp as PAP. The primary objective of the study was to identify the conditions at different risk for an unpredictable absorption of PCZ-susp in order to define the clinical settings in which the formulation can be safely used, without the need of PPC monitoring, as an alternative to PCZ-tab.
Patients and methods

Study population and data collection
This was a prospective, observational study, conducted from October 2012 through September 2013 among 15 hematologic centers in Rome, Florence and Perugia (Italy). The study protocol was approved by the ethics Committees of all participating centers. It was conducted in accordance with good clinical practice and the declaration of Helsinki. Written informed consent from each patient prior to any study-related activity was obtained.
at University of Manchester on March 14, 2016 http://mmy.oxfordjournals.org/ Downloaded from PCZ-susp was administered at standard dose (600 mg/day in adults regardless of the body weight and 20 mg/kg/day in children divided in three administrations). In AL patients prophylaxis was started after the end of chemotherapy and continued until recovery from neutropenia (neutrophil count, > 1,000/mm3) or until another antifungal agent was administered, either empirically or in view of a documented IFD. In allo-SCT recipients prophylaxis was administered during the immunosuppressive therapy for GvHD at the discretion of the responsible physician. Patients were advised to take PCZ-sup after their regular meals. Investigators were asked to take the first blood sample at the end of the first week of PCZ-susp therapy and thereafter every 7-10 days or based on clinical judgment if possible reduction of absorption was suspected. Trough levels were always measured. Blood samples (4.5 ml) for determining PPCs were collected in EDTA or citrate tubes, were immediately centrifuged and separated plasma was stored at -80 • C. Samples were sent by courier to a central referral pharmacology laboratory (Department of Clinical Pharmacology, University of Florence) every two to three weeks. A validated high-pressure liquid chromatography (HPLC) assay was used to measure PPC. 14 The pharmacology laboratory communicated PPC results to each center within few days from samples receipt.
Overall, 103 AL patients undergoing intensive chemotherapy and 46 allo-SCT recipients with GvHD receiving PCZ-susp as PAP during hospitalization or as outpatients were enrolled in this study. As each patient may have received multiple PCZ-susp prophylaxis courses during different chemotherapy cycles or in different periods after allo-SCT the analysis was performed for each PCZ-OS prophylaxis course. Multiple prophylaxis courses per each patient were considered if the drug administration was discontinued for at least 7 days of each other. Discontinuation of the drug for a shorter period was considered a temporary interruption during the same course and was reported in the case report form.
Data were entered into electronic case report forms to collect demographic information, clinical data on adverse events, PCZ-susp dosing information, concomitant medications taken during PCZ-susp therapy and efficacy of PAP. In particular, information on episodes of oral mucositis and diarrhea was recorded in a binary way as grade 0-I or II-IV according to the U.S. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), v4.03. Information on reduced feeding or compliance of taking treatment (defined as relevant at the discretion of the investigator), and on concomitant PPIs treatment during PCZsusp prophylaxis was entered in the medical record.
Cases of breakthrough invasive fungal diseases (IFD) during PCZ-susp prophylaxis were classified according to the definitions of the Invasive Fungal Infection Group of the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) 15 . Cases of empiric antifungal therapy were also recorded.
Analysis
The primary purposes of the study were to describe the PPC patterns (see below) in a "real life" scenario of patients who received PAP at standard doses and to define conditions at different probability of subtherapeutic PPC. The secondary purposes were the evaluation of a possible correlation between PPCs and breakthrough IFDs or empiric antifungal therapy and side effects for each prophylaxis course. Considering that investigators were usually aware of the PPC results after several days from sample collection, frequently when the prophylaxis course was already discontinued, the results could not be generally used for dose modification. Consequently, the impact of a possible modification of the dose was not included in the purposes of this study.
PCZ-susp administration records for each patient were used to verify the time of PPC sampling in relation to the start of treatment. Samples erroneously collected out of the patient's dosing period were excluded from the analysis.
The adequacy of PPC patterns in courses with two or more PPC measurements was defined as follows:
Inadequate PPC pattern: in this group were included courses in which PPC was < 0.5 mcg/ml at least once after the steady state (≥day 7 of treatment). Before the steady state a PPC < 0.35 mcg/ml was considered inadequate. 16 Borderline PPC pattern: in this group were included courses in which PPC was always ≥0.5 mcg/ml but <0.7 mcg/ml at least once after and ≥0.35 mcg/ml before the steady state.
Adequate PPC pattern: in this group were included courses in which PPC was always ≥0.7 mcg/ml after and ≥0.35 mcg/ml before the steady state.
The borderline and adequate PPC patterns were differentiated considering that most of studies associated the cut-off 0.7 mcg/ml to a significantly higher probability of PCZ prophylaxis success rate, but 0.5 mcg/ml was still considered an acceptable cut-off by some authors.
Continuous data were presented as means (+-standard deviations [SD]) or medians (ranges), and categorical data were expressed as numbers (proportions). Univariate analyses were performed using the Fisher exact probability test to compare categorical variables. The independent impact of the variables possibly influencing the PCZ-susp bioavailability and the PPC patterns (inadequate vs borderline/adequate) was assessed by binomial logistic regression analysis. All the probabilities we reported are two-sided. A P-value of <.05 was considered statistically significant. 
Results
Overall, 115 PCZ-susp prophylaxis courses in 103 AL patients and 47 courses in 46 allo-SCT recipients were considered in the study. The characteristics of the patients are described in Table 1 .
Patients with AL undergoing intensive chemotherapy
Along 2610 cumulative days of PCZ-susp administration, 245 PPC measurements were considered in the analysis: 77 samples were taken before steady state (at day 4 to 6 of therapy) and 168 samples at steady state (since day 7 of therapy). The overall mean of all PPCs was 1.03 mg/l +-0.65 mg/l (range, <0.15 to 3.69). Before steady state, PPC was ≥0.35 mcg/ml in 69 of 77 (89.6%) samples. At steady state, a PPC ≥ 0.5 mcg/ml and ≥0.7 mcg/ml was detected in 147 (87.5%) and 122 (72.6%) samples, respectively ( Figure 1A ).
Considering 83 courses in which at least two samples were available, the PPC patterns were distributed as follows: adequate PPC pattern in 53 courses (63.9%), borderline PPC pattern in 12 courses (14.5%) and inadequate PPC pattern in18 courses (21.7%). The cumulative median (range) PPC in courses with adequate, borderline and The correlation between the different PPC patterns and patients clinical variables is detailed in Table 2 . The binomial logistic regression analysis showed a statistically significant association between diarrhea and an inadequate PPC pattern [odds ratio 8.29 (95% CI 2.47 -27.84); P = .001]. Out of 16 prophylaxis courses in which the patient developed grade II-IV diarrhea, an inadequate PPC pattern was demonstrated in 10 (62.5%) cases (relative risk 5.2; 95% CI, 2.46 -11.11; P < .0001). In the courses in which patients did not develop diarrhea, the probability of an inadequate PPC pattern was 11.9% (8 of 67 courses). The time correlation between onset of diarrhea and PPC values during the above 16 prophylaxis courses is detailed in Figure 2A .
Out of 115 prophylaxis courses, treatment was completed until neutrophil recovery in 93 cases (80.9%). PCZ-susp treatment was discontinued before neutrophil recovery in four cases (3.5%) due to patient death and in two cases (1.7%) due to difficult oral intake. In the remaining 16 cases (13.9%) PCZ-susp was shifted to another intravenous antifungal treatment for a proven/probable IFD (three cases), for a possible IFD (five cases), or for purely empirical treatment (eight cases). PCZ-susp was never stopped due to a drug related side effect. The correlation between the reason of PCZ-susp discontinuation and the PPC pattern, in 83 evaluable patients, is detailed in Table 3 . There was a significantly higher shift to another antifungal therapy in prophylaxis courses with an inadequate PPC pattern (P = .007).
Patients submitted to allo-SCT
Along 3589 cumulative days of PCZ-susp administration, 144 PPC measurements in 47 courses were considered in the analysis: 23 samples were taken before steady state (at Figure 1B ). Considering 37 courses in which at least two samples were available, the PPC patterns were distributed as follows: adequate pattern in 23 courses (62.2%), borderline pattern in four courses (10.8%) and inadequate pattern in 10 courses (27.0%). The cumulative median (range) PPC in courses with adequate, borderline and inadequate PPC pattern were 1.63 (0.45-5.74), 1.18 (0.40-4.8), and 0.82 (0.1-2.39) mcg/ml, respectively.
The correlation between the different PPC patterns and patients/clinical variables is detailed in Table 2 . At binomial logistic regression analysis, there was an association close to statistical significance between diarrhea and inadequate PPC pattern [odds ratio 6.85 (95% CI 0.98 -47.6); P = .052].
Out of eight prophylaxis courses in which the patient developed grade II-IV diarrhea the PPC monitoring showed an inadequate PPC pattern in five (62.5%) cases (relative risk 3.6; 95% CI, 1.4 -9.5; P = .09). In the courses in which patients did not develop diarrhea, the probability of an inadequate PPC pattern was 17.2% (5 of 29 courses). The time correlation between onset of diarrhea and PPC values during the above eight prophylaxis courses is detailed in Figure 2B .
Out of 47 prophylaxis courses, treatment was completed according to physician judgment in 41 episodes (87.2%). In four cases (6.4%) PCZ-OS treatment was discontinued due to patient non infectious death. In the remaining two cases PCZ-susp was shifted to another intravenous antifungal treatment for a probable or possible IFD. In these two patients, PPC pattern was inadequate and adequate, respectively. PCZ-susp was never stopped due to a drug related side effect.
Discussion
PCZ-susp has been increasingly used in the real life for PAP in patients with AML and allo-SCT recipients. The recent commercial availability of the PCZ-tab formulation characterized by a better bioavalability and less stringent need for the PPC measurement is expected to trigger an even greater use of PAP with a partial replacement of the old formulation. Nevertheless, in some conditions, such as dysphagia or presence of feeding tubes, PCZ-susp will probably continue to be used.
However, there is no complete agreement on the need of PPC monitoring during PCZ-susp prophylaxis: the ECIL guidelines recommend PPC monitoring in both AML and allo-SCT populations (particularly in patients with intestinal GVHD), while the IDSA guidelines do not recommend routine PPC measurement even though recognize that drug level monitoring may aid in decisions about dosing in some patients. 3, 4 Indeed, there are no definitive data from large trials that address PPC measurement use in every clinical context. Of relevance, while several studies demonstrated that certain factors, such as intestinal diseases, use of PPI and fasting, reduce the bioavailability of PCZ-susp, whether and in what extent this reduction affects the probability in reaching the target serum levels should be defined.
The main results of the published studies on TDM in patients treated with PCZ-susp are summarized in Table 4 . [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The majority of studies showed a correlation between lower PPCs and gastrointestinal diseases, reduced food intake, and use of PPIs. In most cases of breakthrough IFDs the PPCs were under the target level confirm-ing the correlation between the blood levels of the drug and its efficacy, even though failure of PCZ-susp prophylaxis occurred regardless of the PPCs in some studies. 18, 29 Indeed, the results of these studies may be difficult to compare each other considering the different parameters used in the analysis of the data. There were variable definitions of the target plasma level at steady state for prophylaxis (trough level of 0.5 mg/l or 0.7 mg/l), furthermore, there was a variability in describing the PPC patterns. Data on PPC were in some cases reported as the median or the mean of all measurements performed during the treatment courses, while in other cases the rate of courses in which the target (0.5 or 0.7 mg/l) was not reached, even transiently, was also reported. The first way of reporting the data does not take into account the intrapatient variability of the PPCs along the treatment course. For example, in a PCZ-susp prophylaxis course with multiple PPCs over the target and a single measurement under the target the average PPC is largely satisfactory but, during a certain period, the patient may not be protected from infection due to a transitory subtherapeutic blood level of the drug. In the analysis of our study we decided to consider the adequacy of the PPC pattern along the entire prophylaxis course although, due to the limited number of samples collected in some patients, the patterns reported may not be representative of the whole treatment period. The rate of courses in which PPCs were always over the target of 0.5 mg/l and 0.7 mg/l at steady state was 78.4% and 63.9%, respectively, in AL patients, and 73.0% and 62.2%, respectively, in allo-SCT recipients. Although this study was not designed for evaluating the relationship between the PPCs and the efficacy of the PAP, we observed that in AL patients the rate of shift to another antifungal drug was significantly higher in courses with an inadequate PPC pattern. The decision of the investigators to begin a different treatment (either empiric or tailored) was not influenced by the PPC results, which were available in most of the cases too late to guide a therapeutic modification.
In the analysis of factors potentially involved in the PPC patterns, only diarrhea had an impact in both AL and allo-SCT patients. Such correlation has been already reported in several studies. 17, 19, 22, 24, 25, 26, 30 The variable "diarrhea" was not a sensible predictor of an inadequate PPC pattern, considering that several patients with diarrhea still maintained PPCs over 0.5 or 0.7 mcg/ml during the intestinal disease. However, it showed a negative predictive value in term of a low (11.9% in AL and 17.2% in allo-SCT) probability of an inadequate PPC pattern in patients without grade II-IV diarrhea.
This study has a number of limitations, including the non-homogeneous methodology of blood sample collection. Nevertheless, this is the largest prospective experience on PPC monitoring in high-risk hematologic patients receiving PCZ-susp prophylaxis so far reported in literature. Compared to previous studies, generally performed during the first years of PCZ-susp use in the clinical practice, the pharmacokinetic findings we observed were more favorable. Probably, the experience gained in the use of this medication in the hematologic centers, in particular relatively to the co-administration with meals and the monitoring of patient compliance, may have contributed to the optimization of the prophylaxis strategy over the years.
In conclusion, the most important result of our study is that in patients receiving intensive chemotherapy or with GVHD, the probability of an inadequate absorption of PCZ-susp in the absence of diarrhea is low. Although PCZtab will presumably represent the formulation of choice in the PAP of high risk hematological patients, the PCZsusp will still be used in certain patients, particularly those with dysphagia or feeding tubes. Considering that in a large number of centers a timely triazoles blood monitoring is difficult to perform, clinical conditions which may predict a variable bioavailability of the drug can be considered in the clinical practice for the safe use of PCZ-susp without PPC monitoring. . Day 4 : median PPC 0.9 mg/l in group 3, versus 0.57 mg/l in group 1, 0.4 mg/l in group 2, and 0.5 mg/l in group 4 (P<.01). Day 8: median PPC 1.5 mg/l in group 3 versus 0.9 mg/l in group 1, 0.7 mg/l in group 2, and 0.6 mg/l in group 4 (P = .006).
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